Cargando…

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients

Detalles Bibliográficos
Autores principales:	Macías, J, Mallolas, J, López-Cortés, LF, Cartón, JA, Domingo, P, Moreno, S, Iribarren, JA, Neukam, K, Rodrigo, A, Jiménez-Expósito, MJ, Pineda, JA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113099/ http://dx.doi.org/10.1186/1758-2652-13-S4-P91

Ejemplares similares

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship
por: Bhatt, Nilesh B., et al.
Publicado: (2015)

Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models
por: Mastan, SK, et al.
Publicado: (2009)

Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals
por: Mbuagbaw, Lawrence, et al.
Publicado: (2016)

More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort
por: Rokx, Casper, et al.
Publicado: (2014)

Incidence and Determinants of Nevirapine and Efavirenz-Related Skin Rashes in West Africans: Nevirapine's Epitaph?
por: Sarfo, Fred Stephen, et al.
Publicado: (2014)

Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1
por: van Leth, Frank, et al.
Publicado: (2004)

Correction: Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1
Publicado: (2004)

Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
por: Wu, Jingjing, et al.
Publicado: (2019)

Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals
por: Pereira, A, et al.
Publicado: (2010)

Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens
por: Bommenel, T, et al.
Publicado: (2010)

Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study
por: Sinha, Sanjeev, et al.
Publicado: (2013)

The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa
por: Shearer, Kate, et al.
Publicado: (2014)

HAART and the liver: friend or foe?
por: Pineda, JA, et al.
Publicado: (2010)

Proteomic Analysis of Serum and Urine of HIV-Monoinfected and HIV/HCV-Coinfected Patients Undergoing Long Term Treatment with Nevirapine
por: Wongtrakul, Jeerang, et al.
Publicado: (2014)

Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
por: Sinha, Sanjeev, et al.
Publicado: (2017)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

Potential Hepatotoxicity of Efavirenz and Saquinavir/Ritonavir Coadministration in Healthy Volunteers
por: Jamois, Candice, et al.
Publicado: (2009)

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2012)

Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy
por: Banda, Clifford G., et al.
Publicado: (2018)

Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
por: Marima, Rahaba, et al.
Publicado: (2020)

Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya
por: Ngayo, Musa Otieno, et al.
Publicado: (2021)

Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients
por: Mata-Marín, JA, et al.
Publicado: (2010)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral treatment amongst an adult treatment cohort from South Africa
por: Bock, P, et al.
Publicado: (2010)

Outcomes for Efavirenz versus Nevirapine-Containing Regimens for Treatment of HIV-1 Infection: A Systematic Review and Meta-Analysis
por: Pillay, Prinitha, et al.
Publicado: (2013)

Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant
por: Scarsi, Kimberly, et al.
Publicado: (2014)

The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment
por: Skinner-Adams, Tina S., et al.
Publicado: (2012)

Managing HCV/HIV coinfection
por: Danish, Fazal A., et al.
Publicado: (2009)

Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
por: Zuckerman, Autumn D., et al.
Publicado: (2019)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

HCV Coinfection Associated with Slower Disease Progression in HIV-Infected Former Plasma Donors Naïve to ART
por: Zhang, Xiaoyan, et al.
Publicado: (2008)

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
por: Berenguer, Juan, et al.
Publicado: (2019)

Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
por: Fanciulli, Chiara, et al.
Publicado: (2022)

Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy
por: Estrada, Vicente, et al.
Publicado: (2014)

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV‐Infected Subjects With Aging Biomarkers
por: Dumond, JB, et al.
Publicado: (2016)

Clinically relevant enantiomer specific R‐ and S‐praziquantel pharmacokinetic drug‐drug interactions with efavirenz and ritonavir
por: Mutiti, Chenai Sheilla, et al.
Publicado: (2021)

Pharmacogenetics of Efficacy and Safety of HCV Treatment in HCV-HIV Coinfected Patients: Significant Associations with IL28B and SOCS3 Gene Variants
por: Vidal, Francesc, et al.
Publicado: (2012)

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study
por: Teeranaipong, Phairote, et al.
Publicado: (2016)

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana
por: Maseng, Monkgomotsi J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bsk6q8uft5419qlamfmq4cmuc5